Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Lopinavir is a drug against HIV, hydroxychloroquine is used to treat malaria and rheumatism. Until recently, both drugs were regarded as potential agents in the fight against the coronavirus SARS-CoV-2.
Dr. Matteo Daldosso and Dr. Sebastian Wegner discuss novel solutions for the characterization of polymorphs and amorphous form APIs.
Now, a recent trial published on the preprint server medRxiv* in July 2020 reports that a majority of hospitalized COVID-19 patients have a high titer of neutralizing antibodies, at the time of admission, within 10 days of symptomatic disease.
Results from Oxford University’s RECOVERY trial into existing drugs for the treatment of COVID-19 has found that dexamethasone reduced deaths by a third in ventilated coronavirus patients and by a fifth in coronavirus patients requiring oxygen. This is the first drug of its kind to be demonstrated to have a significant impact on COVID-19 mortality.
The British Heart Foundation is funding a trial for an experimental drug that could prevent the life-threatening blood clots that are seen in the lungs of the patients with COVID-19 or those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug named TRV027 is said to normalize the hormonal imbalance that can be seen in patients developing COVID-19, experts said.
A new study by scientists from the U.S and U.K. and published on the preprint server bioRxiv in June 2020 reports that there is no evidence of efficacy for the drug hydroxychloroquine (HCQ) against infection with SARS-CoV-2 in hamsters or macaque models. This finding does not support the current widespread prophylactic and therapeutic use of HCQ in COVID-19.
A new study by an international team of researchers and published on the preprint server medRxiv* in June 2020 describes the possible reasons for inconsistent or null findings in clinical studies of antiviral drugs to date. It proposes a new approach to decide the sample size in light of its findings.
A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.
A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.
Since the outbreak of the COVID-19 pandemic and its rapid spread, the scientific community has been working on developing an effective treatment for the virus responsible for the disease.
As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).
A new study published on the preprint server medRxiv* in May 2020 reports the beneficial effects of the monoclonal antibody sarilumab in severe COVID-19 pneumonia.
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
The world has experienced many outbreaks of viral diseases. Over the past two decades, we have also seen the emergence of zoonotic human respiratory coronaviruses with pandemic potential.
A new study published in the journal Science Immunology in May 2020 reports that compounds that safely inhibit the JAK protein could be useful in treating COVID-19.
The skyrocketing number of cases due to the coronavirus pandemic has taken a massive toll on the health systems in many countries. Since the advent of the coronavirus disease (COVID-19), hundred of research teams are racing to find an effective vaccine and treatment to combat the deadly infection. Now, a team of researchers in Hong Kong suggests that combining three existing antivirals may help treat COVID-19 patients.
A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug used for HIV treatment and prevention may work to prevent COVID-19 infection.
The coronavirus disease (COVID-19) is potentially fatal for vulnerable populations like seniors who over 60 years old, and those with underlying medical conditions, like heart disease, diabetes, and lung disease. Reports show that patients are suffering from heart impairment caused by COVID-19. A new study sheds light on the effect of the novel coronavirus on the heart, causing cardiovascular problems, even in those without underlying heart conditions.
A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.
With the stepwise easing of measures in Switzerland, it is pivotal to monitor for any new COVID-19 outbreaks and to contain them in a timely and effective manner.